Prospectus

MOLECULAR PARTNERS AG (NASDAQ: MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Molecular Partners AG (NASDAQ: MOLN)

Retrieved on: 
Thursday, July 14, 2022
SEC, Partner, News, District court, Cancer, EUA, Investment, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prospectus, Advertising, 506, IPO, Labour government, LLP, GLOBE, Food, Trial of the century, Novartis, The Legal 500, COVID, Securities Act of 1933, American, Lists of action films, ADS, AMG, NEW, Form, Register, Securities Exchange Act of 1934, Class, Company, COVID-19, Molecular Partners, Court, Registration statement, FDA, Special-purpose acquisition company, Defendant, Tobacco, Online gambling, Pharmaceutical industry, Security (finance), Renewable energy, Molecule, Amgen

NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired: (a) Molecular Partners AG (“Molecular Partners” or the “Company”) American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about June 16, 2021 (the “IPO”); and/or (b) Molecular Partners securities between June 16, 2021 and April 26, 2022, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Molecular Partners AG Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Molecular Partners operates as a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic proteins.
  • Among other product candidates, Molecular Partners is developing ensovibep as a treatment for COVID-19 in collaboration with Novartis AG (Novartis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Netcapital Inc. Announces Closing of Public Offering

Retrieved on: 
Friday, July 15, 2022
Technology, Finance, Consulting, Fintech, Banking, Business, Professional Services, Digital Cash Management, Digital Assets, Crowdfunding, Research, SEC, Jumpstart Our Business Startups Act, U.S. Securities and Exchange Commission, Security (finance), Investment, Prospectus, Nasdaq, ThinkEquity, Financial Industry Regulatory Authority, Global Investment in American Jobs Act of 2013, Forward-looking statement, Telephone, Technology, FINRA, Marketing, Form, Company, State Street, Association, SEC filing

The gross proceeds from the offering were $5,000,750 prior to deducting underwriting discounts, commissions, and other offering expenses.

Key Points: 
  • The gross proceeds from the offering were $5,000,750 prior to deducting underwriting discounts, commissions, and other offering expenses.
  • In connection with the closing of the offering, the underwriter partially exercised its over-allotment option and purchased an additional 111,300 warrants.
  • A final prospectus related to the offering has been filed and is available on the SECs website at https://www.sec.gov .
  • Forward-looking statements are based on Netcapital Inc.s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.

KBRA Assigns Preliminary Ratings to Theorem Funding Trust 2022-2

Retrieved on: 
Friday, July 15, 2022
Professional Services, Insurance, Finance, U.S. Securities and Exchange Commission, Insurance commissioner, KBRA, Prospectus, CRA, UK, European Securities and Markets Authority, LLC, Ontario Securities Commission, Jetivia SA v Bilta (UK) Limited (in liquidation), National Association of Insurance Commissioners, National Association, ESG, Credit, Security (finance)

Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above.

Key Points: 
  • Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above.
  • Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at www.kbra.com .
  • Kroll Bond Rating Agency, LLC (KBRA) is a full-service credit rating agency registered with the U.S. Securities and Exchange Commission as an NRSRO.
  • KBRA is also recognized by the National Association of Insurance Commissioners as a Credit Rating Provider.

TD SYNNEX Announces Results of Senior Notes Exchange

Retrieved on: 
Friday, July 15, 2022
Software, Mobile, Wireless, Networks, Internet, Hardware, Data Management, Consumer Electronics, IOT (Internet of Things), Technology, Security, Audio, Video, Other Technology, Telecommunications, Securities Act of 1933, Name, Debt-to-GDP ratio, Expiration, Prospectus, Solution, NYSE, TD, SYNNEX, IOT, Exchange, Company, Exchange offer, Compliance, Note, Expiration date, Synnex, Security (finance)

Under the Exchange Offer, the Company offered to exchange up to (i) $700,000,000 aggregate principal amount of new 1.250% Senior Notes due 2024, (ii) $700,000,000 aggregate principal amount of new 1.750% Senior Notes due 2026, (iii) $600,000,000 aggregate principal amount of new 2.375% Senior Notes due 2028 and (iv) $500,000,000 aggregate principal amount of new 2.650% Senior Notes due 2031 (collectively, the Exchange Notes), the issuance of which has been registered under the Securities Act of 1933, as amended (the "Securities Act"), for a like principal amount of its unregistered (i) $700,000,000 aggregate principal amount of its outstanding 1.250% Senior Notes due 2024 (the Outstanding 2024 Notes), (ii) $700,000,000 aggregate principal amount of its outstanding 1.750% Senior Notes due 2026 (the Outstanding 2026 Notes), (iii) $600,000,000 aggregate principal amount of its outstanding 2.375% Senior Notes due 2028 (the Outstanding 2028 Notes) and (iv) $500,000,000 aggregate principal amount of its outstanding 2.650% Senior Notes due 2031 (the Outstanding 2031 Notes and, together, with the Outstanding 2024 Notes, the Outstanding 2026 Notes and Outstanding 2028 Notes, the Outstanding Notes).

Key Points: 
  • Under the Exchange Offer, the Company offered to exchange up to (i) $700,000,000 aggregate principal amount of new 1.250% Senior Notes due 2024, (ii) $700,000,000 aggregate principal amount of new 1.750% Senior Notes due 2026, (iii) $600,000,000 aggregate principal amount of new 2.375% Senior Notes due 2028 and (iv) $500,000,000 aggregate principal amount of new 2.650% Senior Notes due 2031 (collectively, the Exchange Notes), the issuance of which has been registered under the Securities Act of 1933, as amended (the "Securities Act"), for a like principal amount of its unregistered (i) $700,000,000 aggregate principal amount of its outstanding 1.250% Senior Notes due 2024 (the Outstanding 2024 Notes), (ii) $700,000,000 aggregate principal amount of its outstanding 1.750% Senior Notes due 2026 (the Outstanding 2026 Notes), (iii) $600,000,000 aggregate principal amount of its outstanding 2.375% Senior Notes due 2028 (the Outstanding 2028 Notes) and (iv) $500,000,000 aggregate principal amount of its outstanding 2.650% Senior Notes due 2031 (the Outstanding 2031 Notes and, together, with the Outstanding 2024 Notes, the Outstanding 2026 Notes and Outstanding 2028 Notes, the Outstanding Notes).
  • The terms of the Exchange Notes offered in the Exchange Offer are substantially identical to the terms of the respective series of the Outstanding Notes, except that the Exchange Notes are registered under the Securities Act, and certain transfer restrictions, registration rights, and additional interest provisions relating to the Outstanding Notes do not apply to the Exchange Notes.
  • The Company accepted all of the Outstanding Notes which were validly tendered and not validly withdrawn as of the Expiration Date and issued a like principal amount of Exchange Notes in exchange for such Outstanding Notes.
  • TD SYNNEX, the TD SYNNEX Logo, and all other TD SYNNEX company, product and services names and slogans are trademarks of TD SYNNEX Corporation.

ITHAX Acquisition Corp. Shareholders Approve Business Combination with Mondee

Retrieved on: 
Friday, July 15, 2022
Other Travel, Software, Finance, Travel, Professional Services, Technology, Apps, Applications, Mobile, Wireless, U.S. Securities and Exchange Commission, Registration statement, THE, Prospectus, Communication, Failure, Securities Act of 1933, Register, Silicon, Lists of disasters, SEC, United States Army Acquisition Corps, Investment, Nasdaq, Securities Exchange Act of 1934, Travel, NASDAQ, PIPE, COVID-19, Risk, Growth, Business architecture, Ithaca, Acquisition, Report of the Committee on Company Law Amendment, Form, Cayman, Sale, Software as a service, Security (finance), Online shopping, Property management

ITHAX Acquisition Corp. (ITHAX) (Nasdaq: ITHX), a publicly traded special purpose acquisition company, announced today that shareholders of record as of May 13, 2022, approved the previously proposed business combination (the Business Combination) with Mondee Holdings II, Inc. (Mondee or the Company), the high-growth, travel technology company and marketplace, supported by 69.63% of the shares of ITHAX voted at the extraordinary general meeting of shareholders held on July 15, 2022.

Key Points: 
  • ITHAX Acquisition Corp. (ITHAX) (Nasdaq: ITHX), a publicly traded special purpose acquisition company, announced today that shareholders of record as of May 13, 2022, approved the previously proposed business combination (the Business Combination) with Mondee Holdings II, Inc. (Mondee or the Company), the high-growth, travel technology company and marketplace, supported by 69.63% of the shares of ITHAX voted at the extraordinary general meeting of shareholders held on July 15, 2022.
  • Pursuant to the Business Combination, at the closing, Mondee will merge with ITHAX and the combined companys name will be Mondee Holdings, Inc. (New Mondee).
  • On December 20, 2021, Mondee entered into a definitive business combination agreement with ITHAX Acquisition Corp. (Nasdaq: ITHX) that is expected to result in Mondee becoming a publicly listed company on Nasdaq under the ticker symbol MOND.
  • Additionally, ITHAX will file other relevant materials with the SEC in connection with the proposed business combination of ITHAX with Mondee.

Viveon Health Acquisition Corp. Announces Filing of Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Suneva Medical

Retrieved on: 
Friday, July 15, 2022
Professional Services, Health, Medical Devices, Other Professional Services, Other Health, Finance, General Health, SEC, Name, Regulation, Acquisition, U.S. Securities and Exchange Commission, Registration statement, Patient, THE, Prospectus, Solution, File, Person, Proxy, NYSE American, Private Securities Litigation Reform Act, Failure, Regulation S-X, Forward-looking statement, NYSE, Technology, Health, Ownership, Securities Act of 1933, Ageing, Form, Register, PIPE, Physician, Regenerative medicine, COVID-19, Sale, Standard of care, Risk, Growth, CA, FDA, SPAC, Security (finance), Risk management

The Registration Statement, contains a preliminary proxy statement/prospectus in connection with the previously announced business combination between VHAQ and Suneva .

Key Points: 
  • The Registration Statement, contains a preliminary proxy statement/prospectus in connection with the previously announced business combination between VHAQ and Suneva .
  • While the information within the Registration Statement is subject to change, it provides important information about Suneva Medical and VHAQ, as well as the proposed business combination.
  • Included in the Registration Statement are Sunevas financial results for 2021 and for the first quarter of 2022.
  • Overall, Suneva delivered strong revenue growth in 2021 and generated $29.5 million of net sales and $6.3 million in Q1 of 2022.

AMTD Digital Inc. Announces Successful Pricing of Initial Public Offering with a Pre-Greenshoe Market Capitalization of US$1.433 billion

Retrieved on: 
Friday, July 15, 2022
Technology, Networks, Data Management, Ecosystem, SEC, Terminology, U.S. Securities and Exchange Commission, Electronics, Prospectus, Connaught Road, IPO, Annual report, Greenshoe, Private Securities Litigation Reform Act, Forward-looking statement, NYSE, AMTD, New, Exercise, Marketing, ADS, Attention, Sale, Company, IDEAS Group, Futures, ADSS, Security (finance)

The offering is expected to close on or about July 19, 2022, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about July 19, 2022, subject to the satisfaction of customary closing conditions.
  • The Company raised total gross proceeds of US$124.8 million in the initial public offering, assuming the underwriters of the initial public offering do not exercise their option to purchase additional ADSs.
  • The ADSs are expected to begin trading on the New York Stock Exchange on July 15, 2022, under the ticker symbol HKD, with a pre-greenshoe market capitalization of US$1.443 billion.
  • A registration statement relating to the offering has been filed with, and declared effective by, the U.S. Securities and Exchange Commission.

AMTD IDEA Group Announces Successful Pricing of Initial Public Offering of its Subsidiary AMTD Digital Inc., with a Pre-Greenshoe Market Capitalization of US$1.433 billion

Retrieved on: 
Friday, July 15, 2022
Professional Services, Finance, Ecosystem, SEC, Terminology, U.S. Securities and Exchange Commission, Prospectus, ASEAN, IPO, Private Securities Litigation Reform Act, Forward-looking statement, NYSE, Twitter, AMTD, New, Exercise, HKB, ADS, Sale, Company, IDEAS Group, SGX, ADSS, Security (finance), Public relations

AMTD IDEA Group (AMTD IDEA Group or the Company) (NYSE: AMTD; SGX: HKB), a subsidiary of AMTD Group Company Limited (AMTD Group) and a leading platform for comprehensive financial services and digital solutions, today announced that its controlled subsidiary AMTD Digital Inc. (AMTD Digital), one of the most comprehensive one-stop digital solutions platforms in Asia, successfully priced its initial public offering of 16,000,000 American depositary shares (ADSs), every five ADSs representing two Class A ordinary shares of AMTD Digital, at a price to the public of US$7.80 per ADS.

Key Points: 
  • AMTD IDEA Group (AMTD IDEA Group or the Company) (NYSE: AMTD; SGX: HKB), a subsidiary of AMTD Group Company Limited (AMTD Group) and a leading platform for comprehensive financial services and digital solutions, today announced that its controlled subsidiary AMTD Digital Inc. (AMTD Digital), one of the most comprehensive one-stop digital solutions platforms in Asia, successfully priced its initial public offering of 16,000,000 American depositary shares (ADSs), every five ADSs representing two Class A ordinary shares of AMTD Digital, at a price to the public of US$7.80 per ADS.
  • The ADSs are expected to begin trading on the New York Stock Exchange on July 15, 2022, under the ticker symbol HKD.
  • The offering is expected to close on or about July 19, 2022, subject to the satisfaction of customary closing conditions.
  • A registration statement relating to the offering has been filed by AMTD Digital with, and declared effective by, the U.S. Securities and Exchange Commission.

Regional Health Properties, Inc. Reminds Common Shareholders of Upcoming Special Meeting and Encourages Common Shareholders to Vote

Retrieved on: 
Friday, July 15, 2022
Nursing, Commercial Building & Real Estate, Construction & Property, Other Health, Health, General Health, Public Relations, Investor Relations, Seniors, Communications, Hospitals, Consumer, Transfer, SEC, 2015 Michigan Proposal 1, RHE, Section 10 of the Canadian Charter of Rights and Freedoms, Reading, U.S. Securities and Exchange Commission, Acquisition, Institutional Shareholder Services, THE, Prospectus, Special, Person, Board of directors, Communication, Proxy, Personal Information Agent, NYSE, Schedule, General number field sieve, AS, Eastern Time Zone, SNF, Securities Act of 1933, Exchange, Form, Board, Sale, Company, ANY, Letter, AND, Annual general meeting, Exchange offer, Director, Holding company, Security (finance), Medical device, Right to Make Transmittable

Regional Health Properties, Inc. (NYSE American: RHE) (NYSE American: RHE-PA) (RHE, we or the Company) reminds its common shareholders to vote at the upcoming special meeting (the Special Meeting) to be held on Monday, July 25, 2022 at 10:00 a.m., Eastern Time, at Sonesta Gwinnett Place Atlanta, located at 1775 Pleasant Hill Road, Duluth, Georgia.

Key Points: 
  • Regional Health Properties, Inc. (NYSE American: RHE) (NYSE American: RHE-PA) (RHE, we or the Company) reminds its common shareholders to vote at the upcoming special meeting (the Special Meeting) to be held on Monday, July 25, 2022 at 10:00 a.m., Eastern Time, at Sonesta Gwinnett Place Atlanta, located at 1775 Pleasant Hill Road, Duluth, Georgia.
  • Institutional Shareholder Services (ISS), a leading independent proxy advisory firm, has recommended that common shareholders vote FOR the above Proposals 1 and 2.
  • RHE filed the definitive proxy statement/prospectus (as supplemented or amended) in connection with the proposed transaction with the SEC.
  • Investors should read the definitive proxy statement/prospectus carefully before making any voting or investment decisions.

MOLECULAR PARTNERS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Molecular Partners AG and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, July 15, 2022
Class Action Lawsuit, Professional Services, Legal, SEC, News, U.S. Securities and Exchange Commission, District court, Cancer, EUA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prospectus, Person, 506, IPO, Food, Telephone, Lists of schools in England, Novartis, Jeanne Eagels, Molecule, COVID, ADS, NASDAQ, AMG, Form, Register, Class, COVID-19, P.C, Company, Molecular Partners, Court, Registration statement, FDA, Special-purpose acquisition company, ADSS, Defendant, Security (finance), Pharmaceutical industry, Amgen

Investors have until September 12, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until September 12, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Molecular Partners operates as a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic proteins.
  • Among other product candidates, Molecular Partners is developing ensovibep as a treatment for COVID-19 in collaboration with Novartis AG (Novartis).
  • In addition, Molecular Partners is developing MP0310 (AMG 506) for the treatment of certain types of cancer in collaboration with Amgen Inc. (Amgen).